Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04002115 · ClinicalTrials.gov registry record · Phase 2
Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML
A Phase 2 study, sponsored by Milton S. Hershey Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04002115 is a Phase 2 study that was terminated before completion, run by Milton S. Hershey Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT04002115, a Phase 2 study, was terminated before completion, sponsored by Milton S. Hershey Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The Investigators would like to study the incidence of complete remission (CR) at day +30 after Clofarabine followed by haploidentical transplant. The conditioning regimen used is Fludarabine, Busulfan (2 doses) or cyclophosphamide (2 doses) and Total Body Irradiation (TBI) with post transplant cyclophosphamide for patients with Acute Myeloid Leukemia (AML) who are not in remission prior to considering allogeneic transplant with haploidentical donors.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Clofarabine
- PROCEDURE Total Body Irradiation (TBI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-06-03 |
| Est. Completion | 2022-11-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04002115
The ClinicalTrials.gov registry entry for NCT04002115 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04002115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04002115 about?
NCT04002115 is a clinical study titled "Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML". The Investigators would like to study the incidence of complete remission (CR) at day +30 after Clofarabine followed by haploidentical transplant. The conditioning regimen used is Fludarabine, Busulfan (2 doses) or cyclophosphamide (2 doses) and Total Body Irradiation (TBI) with post transplant cycl...
What is the current status of trial NCT04002115?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-06-03. Estimated completion is 2022-11-07.
What interventions are being tested in trial NCT04002115?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Busulfan (DRUG), Clofarabine (DRUG), Total Body Irradiation (TBI) (PROCEDURE).
Who is sponsoring clinical trial NCT04002115?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.